Jia Ruan, MD, PhD, is an associate professor at Weill Cornell Medical College, discusses sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for mantle cell lymphoma (MCL).

This is the first phase II study to explore the combination of rituximab and lenalidomide, Ruan notes. The study enrolled 38 patients with MCL, of which 84.2% responded to therapy. The complete remission rate with the combination was 52.6%.

The median progression-free survival was not reached after an average of 2 years on therapy. These findings are remarkable, Ruan states, and demonstrated a meaningful response rate and duration.

View more from the 2014 ASH Annual Meeting

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Mantle Cell Lymphoma

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment.  This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

ASH Annual Meeting and Exposition

Jia Ruan, MD, PhD, is an associate professor at Weill Cornell Medical College, discusses sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for MCL.


Dr. Jia Ruan Discusses Lenalidomide Plus Rituximab in MCL